Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

ClinicalTrials.gov ID: NCT00138749

Public ClinicalTrials.gov record NCT00138749. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The Treatment Of Stress Urinary Incontinence (SUI) In Women.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.

Study identification

NCT ID
NCT00138749
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
402 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2004 (Type not available)
Primary completion
Aug 2006 (Actual)
Completion
Aug 2006 (Actual)
Last update posted
Apr 7, 2011

2004 – 2006

United States locations

U.S. sites
89
U.S. states
35
U.S. cities
81
Facility City State ZIP Site status
Pfizer Investigational Site Anchorage Alaska 99508 —
Pfizer Investigational Site Sun City Arizona 85351 —
Pfizer Investigational Site Tucson Arizona 85712-5803 —
Pfizer Investigational Site Tucson Arizona 85712 —
Pfizer Investigational Site Little Rock Arkansas 72205 —
Pfizer Investigational Site Atherton California 94027 —
Pfizer Investigational Site Carmichael California 95608 —
Pfizer Investigational Site Laguna Woods California 92653 —
Pfizer Investigational Site Murrieta California 92562 —
Pfizer Investigational Site Newport Beach California 92660 —
Pfizer Investigational Site Sacramento California 95825 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site Tarzana California 91356 —
Pfizer Investigational Site Temecula California 92591 —
Pfizer Investigational Site Torrance California 90505 —
Pfizer Investigational Site Vista California 92084 —
Pfizer Investigational Site Aurora Colorado 80012 —
Pfizer Investigational Site Denver Colorado 80210 —
Pfizer Investigational Site Denver Colorado 80220 —
Pfizer Investigational Site Wheat Ridge Colorado 80033 —
Pfizer Investigational Site New London Connecticut 06320 —
Pfizer Investigational Site Waterbury Connecticut 06708 —
Pfizer Investigational Site Aventura Florida 33180 —
Pfizer Investigational Site New Port Richey Florida 34652 —
Pfizer Investigational Site Panama City Florida 32405 —
Pfizer Investigational Site Panama City Florida 32407 —
Pfizer Investigational Site Pembroke Pines Florida 33028 —
Pfizer Investigational Site Port Richey Florida 34668 —
Pfizer Investigational Site West Palm Beach Florida 33407 —
Pfizer Investigational Site Alpharetta Georgia 30005 —
Pfizer Investigational Site Coeur d'Alene Idaho 83814 —
Pfizer Investigational Site Arlington Heights Illinois 60004 —
Pfizer Investigational Site Chicago Illinois 60616 —
Pfizer Investigational Site Melrose Park Illinois 60160 —
Pfizer Investigational Site Greenwood Indiana 46143 —
Pfizer Investigational Site Indianapolis Indiana 46202 —
Pfizer Investigational Site Des Moines Iowa 50309 —
Pfizer Investigational Site Louisville Kentucky 40291 —
Pfizer Investigational Site Shreveport Louisiana 71106 —
Pfizer Investigational Site Greenbelt Maryland 20770 —
Pfizer Investigational Site Watertown Massachusetts 02472 —
Pfizer Investigational Site Jackson Mississippi 39202 —
Pfizer Investigational Site Jackson Mississippi 39216 —
Pfizer Investigational Site Liberty Missouri 64068 —
Pfizer Investigational Site North Kansas City Missouri 64116 —
Pfizer Investigational Site Omaha Nebraska 68114 —
Pfizer Investigational Site Henderson Nevada 89014 —
Pfizer Investigational Site Edison New Jersey 08837 —
Pfizer Investigational Site West Orange New Jersey 07052 —
Pfizer Investigational Site Albuquerque New Mexico 87108 —
Pfizer Investigational Site Albany New York 12208 —
Pfizer Investigational Site Garden City New York 11530-1630 —
Pfizer Investigational Site Garden City New York 11530 —
Pfizer Investigational Site Mineola New York 11501 —
Pfizer Investigational Site Poughkeepsie New York 12601 —
Pfizer Investigational Site Burlington North Carolina 27215 —
Pfizer Investigational Site Charlotte North Carolina 28204 —
Pfizer Investigational Site Concord North Carolina 28025 —
Pfizer Investigational Site Fayetteville North Carolina 28304 —
Pfizer Investigational Site Winston-Salem North Carolina 27103 —
Pfizer Investigational Site Cincinnati Ohio 45212 —
Pfizer Investigational Site Bethany Oklahoma 73008 —
Pfizer Investigational Site Eugene Oregon 97401-2676 —
Pfizer Investigational Site Eugene Oregon 97401 —
Pfizer Investigational Site Medford Oregon 97504 —
Pfizer Investigational Site Portland Oregon 97239 —
Pfizer Investigational Site Colmar Pennsylvania 18915 —
Pfizer Investigational Site Lancaster Pennsylvania 17604 —
Pfizer Investigational Site Philadelphia Pennsylvania 19114 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15213 —
Pfizer Investigational Site Sellersville Pennsylvania 18960 —
Pfizer Investigational Site Sewickley Pennsylvania 15143 —
Pfizer Investigational Site Providence Rhode Island 02904 —
Pfizer Investigational Site Charleston South Carolina 29425 —
Pfizer Investigational Site Columbia South Carolina 29201 —
Pfizer Investigational Site Greer South Carolina 29651 —
Pfizer Investigational Site Myrtle Beach South Carolina 29572 —
Pfizer Investigational Site Knoxville Tennessee 37920-1522 —
Pfizer Investigational Site Knoxville Tennessee 37920 —
Pfizer Investigational Site Corpus Christi Texas 78414 —
Pfizer Investigational Site Corsicana Texas 75110 —
Pfizer Investigational Site Houston Texas 77024 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Salt Lake City Utah 84132 —
Pfizer Investigational Site Sandy City Utah 84070 —
Pfizer Investigational Site Sandy City Utah 84094 —
Pfizer Investigational Site West Jordan Utah 84088 —
Pfizer Investigational Site Virginia Beach Virginia 23454 —
Pfizer Investigational Site Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00138749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2011 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00138749 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →